Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 77, Issue 5, 1996, Pages 407-415

  Weido, Anthony J ^c   Reece, Lisa M ^a   Alam, Rafeul ^a   Cook, Cindy K ^b   Sim, Tommy C ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CSB 409 ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; FLUTICASONE PROPIONATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES;

ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOSE SECRETION; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0029731174     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63340-6     Document Type: Article

References (44)

1. Schleimer RP, Benenati SV, Friedman B, Bochner BS. Do cytokines play a role in leukocyte recruitment and activation in the lung? Am Rev Respir Dis 1991;143:1169-74.
2. Borish L. Cytokines and allergy. In: Middleton E Jr, Reed CE, Ellis EF, et al, eds. Allergy principles and practice. 3rd ed, Update no. 9. St. Louis: Mosby, 1991.
3. Alam R, sim TC, Hilsmeier KA, Grant JA. Development of a new technique for recovery of cytokines from inflammatory sites in situ. J Immunol Methods 1992;155:25-9.
4. Weido AJ, Reece LM, Alam R, Sim TC. Secretion profile of chemokines in early and late phase responses in the nasal mucosa: Influence of topical steroid therapy [Abstract]. Ann Allergy Asthma Immunol 1996;76:81.
5. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines. Adv Immunol 1994;55:97-179.
6. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994;15:127-32.
7. Alam R, Lett-Brown MA, Forsythe PA, et al. Monocyte chemotactic and activating factor (MCAF) is a potent histamine-releasing factor for basophils. J Clin Invest 1992;89:723-8.
8. Alam R, Forsythe PA, Stafford S, et al. Macrophage inflammatory protein-1α activates basophils and mast cells. J Exp Med 1992;176:781-6.
9. Dahinden CA, Geiser T, Brunner T, et al. Monocyte chemotactic protein-3 is a most effective basophil and eosinophil activating chemokine. J Exp Med 1994;79:751-6.
10. Alam R, Forsythe PA, Stafford S, et al. Monocyte chemotactic protein-2, monocyte chemotactic protein-3, and fibroblast-induced cytokine. Three new chemokines induce chemotaxis and activation of basophils. J Immunol 1994;153:3155-9.
11. Bascom R, Wachs M, Naclerio RM, et al. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988;81:580-9.
12. Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical steroids. N Engl J Med 1987; 316:1506-10.
13. Sim TC, Hilsmeier KA, Alam R, et al. Effect of topical corticosteroids on the recovery of histamine releasing factors in nasal washings of patients with allergic rhinitis. Am Rev Respir Dis 1992;145:1316-20.
14. Konno A, Yamakoshi T, Terada N, Fujita Y. Mode of action of a topical steroid on immediate phase reaction after antigen challenge and nonspecific nasal hyperreactivity in nasal allergy. Int Arch Allergy Immunol 1994;103: 79-87.
15. Lozewicz S, Wang J, Duddle J, et al. Topical glucocorticoids inhibit activation by allergen in the upper respiratory tract. J Allergy Clin Immunol 1992;89:951-7.
16. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediatory release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128: 597-602.
17. Sim TC, Reece LM, Hilmmeir KA, et al. Secretion of chemokines and other allergen-induced cytokines in nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995;152:927-33.
18. Sim TC, Grant JA, Hilsmeier KA, Alam R. Detection of proinflammatory cytokines in the nasal secretions of allergic subjects following allergen challenge. Am J Respir Crit Care Med 1994;149:339-44.
19. Bitticks LM, Hilsmeier KA, Schreiber DK, Sim TC. Secretion profile of IL-1β and GM-CSF and chemokines (IL-8, MIP-1α, and RANTES) in allergen-induced nasal responses: inhibition by topical corticosteroid pretreatment [Abstract]. J Allergy Clin Immunol 1994;93:270.
20. Hirano T, Akira S, Taga T, et al. Biological and clinical aspects of interleukin 6. Immunol Today 1990;11:443-9.
21. Silberstein DS, Owen WF, Gasson JC, et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunul 1986;137: 3290-5.
22. Lamas AM, Marcotte GV, Schleimer RP. Human endothelial cells prolong eosinophil survival. Regulation by cytokines and glucocorticoids. J Immunol 1989;142:3978-84.
23. White MV, Yoshimura T, Hook W, et al. Neutrophil attractant/activation protein-1 (NAP-1) causes human basophil histamine release. Immunol Lett 1989; 22:151-4.
24. Dahinden CA, Kurimoto Y, De Weck AL, et al. The neutrophil activating peptide NAF/NAP-1 causes histamine and leukotriene release by interleukin-3-primed basophils. J Exp Med 1989; 170:1787-92.
25. Larsen CG, Anderson AO, Appella E, Oppenheim JJ. The neutrophil-activating peptide (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243:1464-6.
26. Sehmi R, Cromwell O, Wardlaw AJ, et al. Interleukin-8 is a chemoattractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. Clin Exp Allergy 1993;23:1027-36.
27. Kuna P, Reddigari SR, Schall TJ, et al. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. J Immunol 1993;150:1932-43.
28. Kuna P, Reddigari SR, Schall TJ, et al. RANTES, a monocyte and T lymphocyte chemotactic cytokine, releases histamine from human basophils. J Immunol 1992;149:636-42.
29. Bischoff SC, Krieger M, Brunner T, Dahinden CA. Monocyte chemotactic protein-1 is a potent activator of human basophils. J Exp Med 1992;175: 1271-5.
30. Alam R, Stafford S, Forsythe PA, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:3442-7.
31. Alam R, Kumar D, Anderson-Walters D, Forsythe PA. Macrophage inflammatory protein-1α and monocyte chemotactic protein-1 elicit immediate and late cutaneous reactions and activate mast cells in vivo. J Immunol 1994;152:1298-303.
32. Meurer R, Van Riper G, Feeney W, et al. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein-1, human macrophage inflammatory protein-1α, or human interleukin 8. J Exp Med 1993;178:1913-21.
33. Alam R, York J, Boyars M, et al. The involvement of chemokines in bronchial asthma. The detection of the mRNA for MCP-1, MCP-3, RANTES, MIP-1α, and IL-8 in bronchoalveolar lavage cells and the measurement of RANTES and MIP-1α in the lavage fluid [Abstract]. Am J Respir Crit Care Med 1994;149:A951.
34. Beck LA, Schall TJ, Beall LD, et al. Detection of the chemokine RANTES and activation of vascular endothelium in nasal polyps [Abstract]. J Allergy Clin Immunol 1994;93:234.
35. Stellato C, Beck LA, Schall TJ, et al. Expression of the chemokine RANTES in human epithelial cells [Abstract]. FASEB J 1994;8:A225.
36. Sousa AR, Lane SJ, Nakhosteen JA, et al. Increased expression of the monocyte chemoattractant protein-1 in bronchial tissue from asthmatic subjects. Am J Respir Mol Cell Biol 1994;10: 142-7.
37. Gillis S, Crabtree GR, Smith KA. Glucocorticosteroid-induced inhibition of T cell growth factor production. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979;123: 1624-31.
38. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5.
39. Kwon OJ, Jose PJ, Robbins RA, et al. Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. Am J Respir Cell Mol Biol 1995; 12:488-96.
40. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in asthma. Drugs 1994;47: 318-31.
41. Masuyama K, Jacobson MR, Raks S, et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 82:192-9.
42. Bradding P, Feather IH, Wilson S, et al. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151:1900-6.
43. Ratner PH, Paull BR, Findlay SR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol 1992;90:285-91.
44. van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone proprionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993;91:1146-54.